{"id":"receipt-of-pcv20","rwe":[],"tags":[],"phase":"preclinical","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"active","trials":["NCT07251465"],"aliases":[],"patents":[],"pricing":[],"allNames":"receipt of pcv20","offLabel":[],"timeline":[],"aiSummary":"PCV20 is a small molecule intervention used to study its effectiveness in preventing all-cause pneumonia and lower respiratory tract infections. PCV20 is being studied in adults who have a higher chance of getting pneumonia.","brandName":"Receipt of PCV20","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"","drugClass":"The main exposure of interest will be receipt of PCV20.","explanation":"PCV20 is a vaccine that helps your body's immune system prepare for potential pneumococcal infections. The vaccine contains small pieces of 20 different strains of pneumococcal bacteria (harmless fragments, not live bacteria) that are linked to a carrier protein. When you receive the vaccine, your immune system learns to recognize these bacterial pieces as invaders and develops antibodies and immune memory to fight them off.\n\nIf you later encounter any of these 20 pneumococcal strains in real life, your immune system is already primed and ready to attack. This prevents the bacteria from establishing an infection or significantly reduces the severity of illness if infection does occur. Because PCV20 covers 20 different strains, it provides broader protection than earlier pneumococcal vaccines that only covered 13 strains.\n\nThis vaccine is particularly important because pneumococcal bacteria can cause serious infections including pneumonia, meningitis, and bloodstream infections, especially in older adults and people with certain medical conditions. By receiving PCV20, you give your body the tools to prevent these potentially life-threatening infections before they start.","oneSentence":"The main exposure of interest will be receipt of PCV20.","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"receipt-of-pcv20","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Pneumonia","phase":"preclinical","trialId":"","patients":null,"diseaseId":"infectious-disease","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07251465","phase":"N/A","title":"A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneu","status":"Not Yet Recruiting","sponsor":"Pfizer","isPivotal":false,"enrollment":846279,"indication":"Pneumonia","completionDate":"2026-03","primaryEndpoint":"The purpose of this study is to learn how effective is PCV20 to help stop adults from getting pneumonia."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"crossReferences":{"chemblId":"CHEMBL3770173"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}